September 29, 2025/
Seyraline, multiple acyl-coenzyme A dehydrogenase deficiency(MADD), Sulfamethoxazole, Trimethoprim (Cotrimoxazole), Circulatory shock
ALVigiLance is a dedicated pharmacovigilance platform designed to support the healthcare team in ensuring safer medication use. Our mission is simple yet vital: to provide trusted insights, practical tools, and up-to-date resources that empower healthcare professionals to identify, prevent, and manage adverse drug reactions (ADRs).
Simplified, practical guides on drug safety and monitoring.
Real-world examples to strengthen your clinical decision-making.
Summaries of global drug warnings and regulatory actions.
Strategies for adverse event reporting, risk management, and patient counseling.
To create a proactive community of healthcare providers who champion medication safety and improve patient outcomes through shared knowledge and vigilance.
Medication safety is everyone’s responsibility. Explore, learn, and engage with ALVigiLance — because together, we can reduce risks and save lives.
Seyraline, multiple acyl-coenzyme A dehydrogenase deficiency(MADD), Sulfamethoxazole, Trimethoprim (Cotrimoxazole), Circulatory shock
Oxytetracycline HCl, Hydrocortisone Acetate, Polymyxin B Sulfate (Ear/Eye Drops/Ointment), Hearing and vestibular disorders, Regorafenib, Stivarga, Hyperammonaemia, hyperammonaemic encephalopathy
Teysuno (tegafur, gimeracil,and oteracil), Hyperammonaemia
